Value of Minimal Residual Disease-Negative Status at Response Evaluation in CLL


Value of Minimal Residual Disease-Negative Status at Response Evaluation in CLL
Slides from a presentation at ASH 2014 and transcribed comments from recent interviews with Mitchell R Smith, MD, PhD (3/24/15) and Ian W Flinn, MD, PhD (3/25/15)
Kovacs G et al. Value of minimal residual disease (MRD) negative status at response evaluation in chronic lymphocytic leukemia (CLL): Combined analysis of two phase III studies of the German CLL Study Group (GCLLSG). Proc ASH 2014;Abstract 23.

Dr Smith is Director of the Lymphoid Malignancies Program at the Cleveland Clinic’s Taussig Cancer Institute in Cleveland, Ohio.

Dr Flinn is Director of Blood Cancer Research at Sarah Cannon Research Institute in Nashville, Tennessee.